Accès gratuit
Med Sci (Paris)
Volume 28, Numéro 10, Octobre 2012
Page(s) 813 - 816
Section Nouvelles
Publié en ligne 12 octobre 2012
  1. Central brain tumor registry of the United States. (consulté le 26 avril 2012). [Google Scholar]
  2. Van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma : a clinician’s perspective. Acta Neuropathol 2010 ; 120 : 297–304. [CrossRef] [PubMed] [Google Scholar]
  3. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000 ; 18 : 636–645. [PubMed] [Google Scholar]
  4. Quon H, Abdulkarim B. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev 2008 : CD007104. [PubMed] [Google Scholar]
  5. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010 ; 75 : 1560–1566. [CrossRef] [PubMed] [Google Scholar]
  6. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of 0-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004 ; 10 : 1871–1874. [CrossRef] [PubMed] [Google Scholar]
  7. Everhard S, Kaloshi G, Criniere E, et al. MGMT methylation : a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006 ; 60 : 740–743. [CrossRef] [PubMed] [Google Scholar]
  8. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011 ; 20 : 810–817. [CrossRef] [PubMed] [Google Scholar]
  9. Juillerat-Jeanneret L, Bernasconi CC, Bricod C, et al. Heterogeneity of human glioblastoma : glutathione-S-transferase and methylguanine-methyltransferase. Cancer Invest 2008 ; 26 : 597–609. [CrossRef] [PubMed] [Google Scholar]
  10. Bonavia R, Inda MM, Cavenee WK, et al. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011 ; 71 : 4055–4060. [CrossRef] [PubMed] [Google Scholar]
  11. Yung WK, Vredenburgh JJ, Cloughesy TF, et al. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 2010 ; 12 : 1061–1070. [CrossRef] [PubMed] [Google Scholar]
  12. Paulsson J, Lindh MB, Jarvius M, et al. Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int J Cancer 2010 ; 128 : 1981–1988. [CrossRef] [Google Scholar]
  13. Natsume A, Kinjo S, Yuki K, et al. Glioma-initiating cells and molecular pathology: implications for therapy. Brain Tumor Pathol 2011 ; 28 : 1–12. [CrossRef] [PubMed] [Google Scholar]
  14. Ducray F, Mokhtari K, Criniere E, et al. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer 2011 ; 47 : 802–808. [CrossRef] [PubMed] [Google Scholar]
  15. SongTao Q, Lei Y, Si G, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2011 ; 103 : 269–273. [CrossRef] [PubMed] [Google Scholar]
  16. Van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009 ; 27 : 5881–5886. [CrossRef] [PubMed] [Google Scholar]
  17. Jha P, Suri V, Jain A, et al. 06-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Neurosurgery 2010 ; 67 : 1681–1691. [CrossRef] [PubMed] [Google Scholar]
  18. Zawlik I, Vaccarella S, Kita D, et al. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology 2009 ; 32 : 21–29. [CrossRef] [PubMed] [Google Scholar]
  19. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003 ; 63 : 5821–5828. [PubMed] [Google Scholar]
  20. Molina JR, Hayashi Y, Stephens C, et al. Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia 2010 ; 12 : 453–463. [PubMed] [Google Scholar]
  21. Hoelzinger DB, Mariani L, Weis J, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005 ; 7 : 7–16. [CrossRef] [PubMed] [Google Scholar]
  22. Gole B, Huszthy PC, Popovic M, et al. The regulation of cysteine cathepsins and cystatins in human gliomas. Int J Cancer 2012 (online). doi : 10.1002/ijc.27453. [Google Scholar]
  23. Mariani L, Beaudry C, McDonough WS, et al. Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro. Clin Cancer Res 2001 ; 7 : 2480–2489. [PubMed] [Google Scholar]
  24. Seidel S, Garvalov BK, Wirta V, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010 ; 133 : 983–995. [CrossRef] [PubMed] [Google Scholar]
  25. Rong Y, Durden DL, Van Meir EG, et al. Pseudopalisading necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006 ; 65 : 529–539. [CrossRef] [PubMed] [Google Scholar]
  26. Charalambous C, Chen TC, Hofman FM. Characteristicsof tumor-associated endothelial cells derived from glioblastoma multiforme. Neurosurg Focus 2006 ; 20 : E22. [CrossRef] [PubMed] [Google Scholar]
  27. Miebach S, Grau S, Hummel V, et al. Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades. J NeuroOncol 2006 ; 76 : 39–48. [CrossRef] [PubMed] [Google Scholar]
  28. Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992 ; 52 : 5334–5341. [PubMed] [Google Scholar]
  29. Shih AH, Holland EC. Notch signaling enhances nestin expression in gliomas. Neoplasia 2006 ; 8 : 1072–1082. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.